Rheumatology Advance Access originally published online on March 5, 2009
Rheumatology 2009 48(5):591-592; doi:10.1093/rheumatology/kep035
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
LETTERS TO THE EDITOR |
Clinical, serological and HLA profiles in non-Caucasian UK idiopathic inflammatory myopathy
1Centre for Integrated Genomic Medical Research, The University of Manchester, 2The University of Manchester Rheumatic Diseases Centre, Salford Royal NHS Foundation Trust, Salford, UK and 3Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, USA on behalf of the UK Adult Onset Myositis Immunogenetic Collaboration
Correspondence to: Robert G. Cooper, The University of Manchester Rheumatic Diseases Centre, Salford Royal NHS Foundation Trust, Stott Lane, Salford M6 8HD, UK. E-mail: robert.g.cooper@manchester.ac.uk
| The first 10% of the full text of this article appears below. |
SIR, Since 2000, the UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC) has recruited idiopathic inflammatory myopathy (IIM) cases across the UK. In this brief report, we summarize the clinical, serological and HLA Class II status of non-Caucasian IIM cases, to ascertain whether differences are observed among UK IIM ethnic populations.
DNA was available from 28 UK non-Caucasian IIM cases. Adult IIM patients, aged
18 years of age at disease onset, with probable or definite myositis [1] were recruited through AOMIC